The evaluation of TLR1, TLR2, TLR4, TLR7, and TLR8 expression levels in the newly-diagnosed acute myeloid leukemia (AML) patients

Fateh, Kosar; Kashani, Bahareh; Hasanpour, Zahra; Shagerdi Esmaeli, Naser; Amiri, Vahid; Ghaffari, Seyed H.; Bashash, Davood

doi:10.58209/ijbc.14.4.95

Volume 14, Issue 4 ( December 2022 2022) Iranian Journal of Blood and Cancer 2022, 14(4): 95-103 | Back to browse issues page

‎ 10.58209/ijbc.14.4.95

Mendeley

Zotero

RefWorks

Fateh K, Kashani B, Hasanpour Z, Shagerdi Esmaeli N, Amiri V, Ghaffari S H et al . The evaluation of TLR1, TLR2, TLR4, TLR7, and TLR8 expression levels in the newly-diagnosed acute myeloid leukemia (AML) patients. Iranian Journal of Blood and Cancer 2022; 14 (4) :95-103
URL: http://ijbc.ir/article-1-1357-en.html

The evaluation of TLR1, TLR2, TLR4, TLR7, and TLR8 expression levels in the newly-diagnosed acute myeloid leukemia (AML) patients

Kosar Fateh¹

, Bahareh Kashani²

, Zahra Hasanpour¹

, Naser Shagerdi Esmaeli¹

, Vahid Amiri¹

, Seyed H. Ghaffari²

, Davood Bashash ^*³

1- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran , david_5980@yahoo.com

Abstract: (1424 Views)

Background: Acute myeloid leukemia (AML) is described by the clonal expansion of myeloid blasts with abnormal differentiation. Considering the role of Toll-like receptors (TLRs) in inflammation induction and the effect of chronic inflammation on cancer development, investigating the state of TLRs’ expression in human malignancies has attracted scientists’ attention.
Methods: In this study, 36 newly-diagnosed AML patients and 36 control samples were examined. The mRNA expression levels of TLR1/2/4/7/8 were measured in both groups using real-time PCR. The student’s t-test was utilized to compare gene expression levels between the two populations and the one-way ANOVA test was used to compare data among multiple subtypes.
Results: All TLR gene expression levels were significantly up-regulated in patients compared to the control group (p<0.05). Positive correlations between different TLRs were observed as well. AML patients under the age of 55 showed significantly higher TLR1/2/4 expression in comparison with healthy individuals of the same age; a similar comparison in people above 55 also showed an elevated expression of TLR1/2/4/8. Male patients overexpressed almost all genes compared to healthy subjects; the levels of TLR1/2/4 were also higher in female patients. No difference was observed comparing blast percentages and FAB subtypes.
Conclusion: By considering the results of this experiment, it seems that TLRs up-regulation in AML patients may contribute to the pathogenesis and development of the disease; however, more investigations are required to elucidate the exact roles of these receptors in AML.

./files/site1/files/Supplementary_Fig._1.docx

Keywords: Acute myeloid leukemia (AML), Toll-like receptor (TLR), Gene expression, Pathogenesis, Inflammation

Full-Text [PDF 1013 kb] (962 Downloads)

: Original Article | Subject: Adults Hematology & Oncology
Received: 2022/10/20 | Accepted: 2022/12/15 | Published: 2022/12/28

References

1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood cancer journal. 2016;6(7):e441-e. [DOI:10.1038/bcj.2016.50]

2. Ramzi M, Khalafi-Nezhad A, Saadi MI, Jowkar Z. Association between TLR2 and TLR4 expression and response to induction therapy in acute myeloid leukemia patients. International journal of hematology-oncology and stem cell research. 2018;12(4):303. [DOI:10.18502/ijhoscr.v12i4.109]

3. Panuzzo C, Signorino E, Calabrese C, Ali MS, Petiti J, Bracco E, Cilloni D. Landscape of tumor suppressor mutations in acute myeloid leukemia. Journal of clinical medicine. 2020;9(3):802. [DOI:10.3390/jcm9030802]

4. Gupta SD, Sachs Z. Novel single-cell technologies in acute myeloid leukemia research. Translational Research. 2017;189:123-35. [DOI:10.1016/j.trsl.2017.07.007]

5. Winer ES, Stone RM. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Therapeutic advances in hematology. 2019;10:2040620719860645. [DOI:10.1177/2040620719860645]

6. Brenner AK, Bruserud Ø. Functional toll-like receptors (TLRs) are expressed by a majority of primary human acute myeloid leukemia cells and inducibility of the TLR signaling pathway is associated with a more favorable phenotype. Cancers. 2019;11(7):973. [DOI:10.3390/cancers11070973]

7. De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine. 2015;74(2):181-9. [DOI:10.1016/j.cyto.2015.02.025]

8. Mokhtari Y, Pourbagheri‐Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll‐like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. Journal of Cellular and Molecular Medicine. 2021;25(2):639-51. [DOI:10.1111/jcmm.16214]

9. Rybka J, Butrym A, Wróbel T, Jaźwiec B, Bogucka-Fedorczuk A, Poręba R, Kuliczkowski K. The expression of toll-like receptors in patients with B-cell chronic lymphocytic leukemia. Archivum Immunologiae et Therapiae Experimentalis. 2016;64(1):147-50. [DOI:10.1007/s00005-016-0433-7]

10. Takizawa H, Manz MG. Impact of inflammation on early hematopoiesis and the microenvironment. International Journal of Hematology. 2017;106(1):27-33. [DOI:10.1007/s12185-017-2266-5]

11. Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S. Association of TLR2 and TLR4 polymorphisms with risk of cancer: a meta-analysis. PloS one. 2013;8(12):e82858. [DOI:10.1371/journal.pone.0082858]

12. Bennett J, Starczynowski DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 2022;29(1):8-19. [DOI:10.1097/MOH.0000000000000693]

13. Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells. Blood advances. 2017;1(23):2046-57. [DOI:10.1182/bloodadvances.2017006148]

14. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27(9):1832-40. [DOI:10.1038/leu.2013.180]

15. Baakhlagh S, Kashani B, Zandi Z, Bashash D, Moradkhani M, Nasrollahzadeh A, Yaghmaei M, Mousavi SA, Ghaffari SH. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation. International immunopharmacology. 2021;90:107202. [DOI:10.1016/j.intimp.2020.107202]

16. Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis‐Mortari A, Chen W, Blazar BR, Miller JS. Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. American journal of hematology. 2012;87(10):953-6. [DOI:10.1002/ajh.23280]

17. Hossain DMS, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood, The Journal of the American Society of Hematology. 2014;123(1):15-25. [DOI:10.1182/blood-2013-07-517987]

18. Härter L, Mica L, Stocker R, Trentz O, Keel M. Increased expression of toll-like receptor-2 and-4 on leukocytes from patients with sepsis. Shock. 2004;22(5):403-9. [DOI:10.1097/01.shk.0000142256.23382.5d]

19. Armstrong L, Medford A, Hunter K, Uppington K, Millar A. Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clinical & Experimental Immunology. 2004;136(2):312-9. [DOI:10.1111/j.1365-2249.2004.02433.x]

20. Monlish DA, Bhatt ST, Schuettpelz LG. The role of toll-like receptors in hematopoietic malignancies. Frontiers in immunology. 2016;7:390. [DOI:10.3389/fimmu.2016.00390]

21. Rybka J, Butrym A, Wróbel T, Jaźwiec B, Stefanko E, Dobrzyńska O, Poręba R, Kuliczkowski K. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy. Leukemia research. 2015;39(3):318-22. [DOI:10.1016/j.leukres.2015.01.002]

22. Kashani B, Zandi Z, Pourbagheri‐Sigaroodi A, Bashash D, Ghaffari SH. The role of toll‐like receptor 4 (TLR4) in cancer progression: A possible therapeutic target? Journal of Cellular Physiology. 2021;236(6):4121-37. [DOI:10.1002/jcp.30166]

23. Kashani B, Zandi Z, Bashash D, Zaghal A, Momeny M, Poursani EM, Pourbagheri-Sigaroodi A, Mousavi SA, Ghaffari SH. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid). Cancer Chemotherapy and Pharmacology. 2020;85(1):47-59. [DOI:10.1007/s00280-019-03988-y]

24. Zandi Z, Kashani B, Bashash D, Poursani EM, Mousavi SA, Chahardoli B, Ghaffari SH. The anticancer effect of the TLR4 inhibition using TAK‐242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer. Journal of cellular biochemistry. 2020;121(2):1623-34. [DOI:10.1002/jcb.29397]

25. Kashani B, Zandi Z, Karimzadeh MR, Bashash D, Nasrollahzadeh A, Ghaffari SH. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers. Immunologic Research. 2019;67(6):505-16. [DOI:10.1007/s12026-019-09113-8]

26. Ran S. The role of TLR4 in chemotherapy-driven metastasis. Cancer research. 2015;75(12):2405-10. [DOI:10.1158/0008-5472.CAN-14-3525]

27. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, The Journal of the American Society of Hematology. 2007;110(1):296-304. [DOI:10.1182/blood-2006-10-051482]

28. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006;20(6):1130-7. [DOI:10.1038/sj.leu.2404226]

29. Eriksson M, Peña P, Chapellier M, Högberg C, Fioretos T, Ebert BL, Järås M. Toll-like receptor 1 is a candidate therapeutic target in acute myeloid leukemia. American Society of Hematology Washington, DC; 2014. [DOI:10.1182/blood.V124.21.5782.5782]

30. Webb R, Cruse J, Lewis R. Decreased TLR4 gene expression in leukemic leukocyte populations. Experimental and molecular pathology. 2009;87(2):117-26. [DOI:10.1016/j.yexmp.2009.07.007]

31. Reuven EM, Fink A, Shai Y. Regulation of innate immune responses by transmembrane interactions: lessons from the TLR family. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2014;1838(6):1586-93. [DOI:10.1016/j.bbamem.2014.01.020]

32. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Toll-Like Receptors (TLRs) and Innate Immunity. 2008:71-86. [DOI:10.1007/978-3-540-72167-3_4]

33. Keshavarz A, Pourbagheri‐Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists. IUBMB life. 2021;73(1):10-25. [DOI:10.1002/iub.2412]

34. Rolf N, Kariminia A, Ivison S, Reid GS, Schultz KR. Heterodimer‐specific TLR2 stimulation results in divergent functional outcomes in B‐cell precursor acute lymphoblastic leukemia. European journal of immunology. 2015;45(7):1980-90. [DOI:10.1002/eji.201444874]

35. Ignatz-Hoover JJ, Wang H, Moreton SA, Chakrabarti A, Agarwal MK, Sun K, Gupta K, Wald DN. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia. 2015;29(4):918-26. [DOI:10.1038/leu.2014.293]

36. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. The Journal of Immunology. 2002;169(9):4697-701. [DOI:10.4049/jimmunol.169.9.4697]

37. Torres-Ruiz J, Carrillo-Vazquez DA, Padilla-Ortiz DM, Vazquez-Rodriguez R, Nuñez-Alvarez C, Juarez-Vega G, Gomez-Martin D. TLR expression in peripheral monocyte subsets of patients with idiopathic inflammatory myopathies: association with clinical and immunological features. Journal of Translational Medicine. 2020;18(1):1-12. [DOI:10.1186/s12967-020-02290-3]

38. Lorenzen JM, David S, Richter A, de Groot K, Kielstein JT, Haller H, Thum T, Fliser D. TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease-a prospective follow-up study. Nephrology Dialysis Transplantation. 2011;26(4):1421-4. [DOI:10.1093/ndt/gfq758]

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb